Experimental drug REC-2282 targets NF2 brain tumors in early trial

NCT ID NCT05130866

Terminated Disease control Sponsor: Recursion Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called REC-2282 in people aged 12 and older with progressive meningiomas (brain tumors) linked to NF2 gene mutations. Participants took the drug or a placebo three times a week in cycles. The goal was to see if the drug could slow tumor growth. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REC-2282 (also known as AR-42), a drug taken by mouth
What this could lead to: If it works, this could provide a new treatment option to slow or stop the growth of meningiomas in people with NF2, potentially delaying the need for surgery or radiation.
What could go wrong: This trial was terminated early with only 25 participants, so results are limited. The drug may not work better than placebo, and side effects are possible. More research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neurofibromatosis 2 NF2-related schwannomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMATOSIS TYPE 2

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Children's National Hospital

Washington D.C., District of Columbia, 20010, United States
Columbia University

New York, New York, 10032, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
House Institute

Los Angeles, California, 90057, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Nicklaus Children's Hospital

Miami, Florida, 33155, United States
Sarah Cannon Cancer Institute - HCA Midwest

Overland Park, Kansas, 66211, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
University of California Los Angeles

Los Angeles, California, 90095, United States
University of Florida

Gainesville, Florida, 32611, United States
University of Minnesota / Masonic Cancer Center

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.